Accelerated approval covers post–BTK inhibitor relapsed/refractory MCL, making sonrotoclax the only BCL2 inhibitor specifically approved for this indication. Independent Lugano-assessed efficacy in ...
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417 ...
• BTK inhibitors work by targeting and blocking the BTK enzyme, which is crucial for the survival and growth of cancerous B-cells in mantle cell lymphoma (MCL). This cuts off the cancer cell’s support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results